The global nicotine market is rapidly evolving due to the recent emergence and expansion of novel products, such as e-cigarettes, various vaping devices, and heated tobacco products. Regulators around the world are considering a broad range of policies to minimize uptake of novel products, particularly with regards to restrictions on forms of promotion and product attributes that may enhance their appeal to current non-smokers, especially among adolescents and young people.
Even though the existing studies and data on novel products might be considered limited, mainly concerning the long-term health effects, there is clear evidence that they present a health hazard both for individual users and for public health in general. Ultimately, those 2 categories of risk have to be taken into account from regulatory as well as medical prospective. Current smokers should be encouraged to quit completely, without switching to new harmful alternatives to conventional tobacco, while addressing the danger of smoking renormalisation and prevention measures should be a top-priority on the countries’ tobacco control agenda.